Table 1 Baseline characteristics of patients with ischemic cardiomyopathy with and without events
From: Human epididymis protein 4: a novel predictor of ischemic cardiomyopathy
Variables | Events group (n = 45) | No events group (n = 51) | Total (n = 96) | P-value |
|---|---|---|---|---|
Age (y) | 75 (70–81) | 68 (61–73) | 71 (65–77) | < 0.001 |
Male, n (%) | 28 (62.2%) | 35 (68.6%) | 63 (65.6%) | 0.510 |
BMI (kg/m2) | 23.35 ± 3.48 | 24.09 ± 3.07 | 23.78 ± 3.24 | 0.326 |
Hypertension, n (%) | 28 (62.2%) | 30 (58.8%) | 58 (60.4%) | 0.734 |
Atrial fibrillation, n (%) | 8 (17.8%) | 4 (7.8%) | 12 (12.5%) | 0.142 |
Diabetes, n (%) | 15 (33.3%) | 19 (37.3%) | 34 (35.4%) | 0.688 |
NYHA-FC | 0.006 | |||
II, n (%) | 7 (15.6%) | 21 (41.2%) | 28 (29.2%) | |
III/IV, n (%) | 38 (84.4%) | 30 (58.8%) | 68 (70.9%) | |
LVEF (%) | 32 (27–42) | 33 (30–42) | 33 (29–42) | 0.368 |
LVEDD/BSA (mm/m2) | 35.7(33.8–39.9) | 35.6(33.6–38.5) | 35.6(33.6–39.2) | 0.51 |
NT- proBNP (ng/L) | 7084.0 (3147.0–15,175.5) | 1874.5 (937.7–4902.7) | 3682.0 (1247.0–21,403.4) | < 0.001 |
HE4 (pmol/L) | 188.7 (113.3–326.8) | 92.9 (61.50–123.2) | 117.6 (80.1–196.8) | < 0.001 |
eGFR (mL/min/1.73 m2) | 53.72 ± 23.48 | 77.04 ± 25.48 | 66.11 ± 27.09 | < 0.001 |
WBC (109/L) | 6.74 (5.35–8.85) | 6.26 (5.33–7.15) | 6.48 (5.34–7.84) | 0.187 |
LDL-C(mmol/L) | 2.44 (1.88–2.79) | 2.33 (1.73–3.36) | 2.37 (1.85–3.07) | 0.519 |
ALT (U/L) | 16.5 (11.0–42.8) | 18.5 (13.8–31.7) | 17.6 (12.2–35.4) | 0.436 |
HbA1c (%) | 5.75 (5.50–6.50) | 6.00 (5.53–6.93) | 5.90 (5.50–6.70) | 0.389 |
CK-MB(U/L) | 13.0 (0.5–22.0) | 14.5 (10.0–20.0) | 13.0 (0–20.0) | 0.887 |
PCI, n (%) | 20 (44.4%) | 30 (58.8%) | 50 (52.1%) | 0.159 |
Diuretics, n (%) | 32 (71.1%) | 30 (58.8%) | 62 (64.6%) | 0.209 |
ACEI/ARB/ARNI, n (%) | 34 (81.0%) | 46 (90.2%) | 80 (86.0%) | 0.201 |
β-Blocker, n (%) | 37 (82.2%) | 47 (92.2%) | 84 (87.5%) | 0.142 |